Current Report Filing (8-k)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported):

April 14, 2015

(Exact name of registrant as specified in its charter)



New Jersey	I-3215	22-1024240
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933

(Address of Principal Executive Offices)

(Zip Code)

Registrant's telephone number, including area code:

732-524-0400

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17

CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17

CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition

On April 14, 2015, Johnson & Johnson issued the attached press release announcing its sales and earnings for the first quarter ended March 29, 2015.

Item 9.01 Financial Statements and Exhibits



Exhibit No.	Description of Exhibit
99.15	Press Release dated April 14, 2015 for the period ended March 29, 2015.
99.2O	Unaudited Comparative Supplementary Sales Data and Condensed Consolidated Statement of Earnings for the first quarter.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



	Johnson & Johnson
		(Registrant)
Date: April 14, 2015	By:	/s/ Stephen J. Cosgrove
		Stephen J. Cosgrove Controller (Principal Accounting Officer)

Exhibit 99.15

Johnson & Johnson Reports 2015 First-Quarter Results:

Sales of $17.4 Billion decreased 4.1% Versus 2014 First Quarter;

First-Quarter EPS was $1.53

Adjusted 2015 First-Quarter EPS of $1.56 Decreased 4.3%*

New Brunswick, N.J. (April 14, 2015) - Johnson & Johnson (NYSE: JNJ) today announced sales of $17.4 billion for the first quarter of 2015, a decrease of 4.1% as compared to the first quarter of 2014. Operational results increased 3.1% and the negative impact of currency was 7.2%. Domestic sales increased 5.9%. International sales decreased 12.4%, reflecting operational growth of 0.8% and a negative currency impact of 13.2%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 5.7%, domestic sales increased 9.1% and international sales increased 3.0%.*

Net earnings and diluted earnings per share for the first quarter of 2015 were $4.3 billion and $1.53, respectively. First-quarter 2015 net earnings included after-tax intangible amortization expense of approximately $0.2 billion and a net gain of after-tax special items of approximately $0.1 billion, primarily related to net litigation gains partially offset by costs related to the DePuy ASR™ Hip program. First-quarter 2014 net earnings included after-tax intangible amortization expense of approximately $0.3 billion and a net gain of after-tax special items of approximately $0.3 billion as shown in the accompanying reconciliation of non-GAAP financial measures. Excluding after-tax intangible amortization expense and special items, adjusted net earnings for the current quarter were $4.4 billion and adjusted diluted earnings per share were $1.56, representing decreases of 5.9% and 4.3%, respectively, as compared to the same period in 2014.*

“The company delivered strong underlying growth in the first quarter driven by new products and the strength of the core business. Of note is the continued robust growth of the Pharmaceutical business and the solid performance of our Consumer brands,” said Alex Gorsky, Chairman and Chief Executive Officer. “I am proud of our global teams who focus every day on delivering innovative solutions to address evolving health care needs.”

The Company updated its adjusted earnings guidance for full-year 2015 to $6.04 - $6.19 per share reflecting further negative foreign currency movements. The Company’s guidance excludes the impact of after-tax intangible amortization expense and special items.

Worldwide Consumer sales of $3.4 billion for the first quarter represented a decrease of 4.7% versus the prior year, consisting of an operational increase of 3.4% and a negative impact from currency of 8.1%. Domestic sales increased 3.8%; international sales decreased 9.7%, which reflected an operational increase of 3.1% and a negative currency impact of 12.8%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 4.7%, domestic sales increased 5.1% and international sales increased 4.5%.*

Positive contributors to operational results were sales of TYLENOL^® and MOTRIN^® analgesics, digestive health and international upper-respiratory over-the-counter products; NEUTROGENA^® and AVEENO^®skin care products; LISTERINE^® oral care products; international sales of feminine protection products; and domestic sales of baby care products.

Worldwide Pharmaceutical sales of $7.7 billion for the first quarter represented an increase of 3.0% versus the prior year with operational growth of 10.2% and a negative impact from currency of 7.2%. Domestic sales increased 16.9%; international sales decreased 10.7%, which reflected an operational increase of 3.7% and a negative currency impact of 14.4%.

The strong operational sales results were driven by new products and the strength of core products. New products include INVOKANA^®/INVOKAMET^® (canagliflozin), for the treatment of adults with type 2 diabetes; XARELTO^® (rivaroxaban), an oral anticoagulant; IMBRUVICA^® (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, or blood cancers; ZYTIGA^® (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer; and international sales of OLYSIO^®(simeprevir), for combination treatment of chronic hepatitis C in adult patients. New product sales growth was negatively impacted by lower sales of OLYSIO^®(simeprevir)in the U.S. and lowersales of SOVRIAD^®(simeprevir) in Japan due to competitive entrants.

Additional contributors to operational sales growth were STELARA^® (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis; CONCERTA^®(methylphenidate HCI), for the treatment of attention deficit hyperactivity disorder; INVEGA^®SUSTENNA^®/XEPLION^® (paliperidone palmitate), a once-monthly, long-acting, injectable atypical antipsychotic for the treatment of schizophrenia in adults; SIMPONI^®/SIMPONI ARIA^® (golimumab) and domestic sales of REMICADE^® (infliximab), biologics approved for the treatment of a number of immune-mediated inflammatory diseases.

During the quarter, the U.S. Food and Drug Administration (FDA) granted approval of IMBRUVICA^®(ibrutinib) for the treatment of Waldenström's Macroglobulinemia and for PREZCOBIX™ (darunavir/cobicistat) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1). The European Commission approved VELCADE^® (bortezomib) in combination with rituximab, cyclophosphamide, doxorubicin and prednisone for the treatment of adult patients with previously untreated mantle cell lymphoma.

In addition, the acquisition of XO1 Limited, a privately-held biopharmaceutical company developing the anti-thrombin antibody ichorcumab, was completed. In April, the divestiture of the U.S. license rights to NUCYNTA^® (tapentadol), NUCYNTA^® ER (tapentadol extended-release tablets), and NUCYNTA^® (tapentadol) oral solution was completed for $1.05 billion.

Worldwide Medical Devices sales of $6.3 billion for the first quarter represented a decrease of 11.4% versus the prior year consisting of an operational decrease of 4.6% and a negative currency impact of 6.8%. Domestic sales decreased 6.1%; international sales decreased 15.6%, which reflected an operational decrease of 3.3% and a negative currency impact of 12.3%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 1.3%, domestic sales increased 1.1% and international sales increased 1.5%.*

Primary contributors to operational growth were sales of Orthopaedic products; electrophysiology products in the Cardiovascular Care business; endocutters in the Surgical Care business; and sales of insulin delivery products in the Diabetes Care business. Sales results in the Vision Care business were negatively impacted by buying patterns and competitive pricing dynamics.

During the quarter, the Company announced a binding offer from Cardinal Health to acquire its Cordis business for an aggregate value of $1.99 billion.

About Johnson & Johnson

Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 127,000 employees at more than 265 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

* Operational sales growth excluding the net impact of acquisitions and divestitures, as well as adjusted net earnings and adjusted diluted earnings per share excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the Company’s website at www.investor.jnj.com.

Johnson & Johnson will conduct a conference call with investors to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.

Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including a pharmaceutical pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can be found on the Company's website at www.investor.jnj.com.

NOTE TO INVESTORS

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges and uncertainties inherent in new product development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; the ability of the company to successfully execute strategic plans; impact of business combinations and divestitures; challenges to patents; the impact of patent expirations; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; increased scrutiny of the health care industry by government agencies; and the potential failure to meet obligations in compliance agreements with government bodies. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 28, 2014, including Exhibit 99 thereto, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.investor.jnj.com, or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.

Exhibit 99.2O



Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)	FIRST QUARTER

	2015			2014			Percent
			Percent			Percent	Increase
	Amount		to Sales	Amount		to Sales	(Decrease)
Sales to customers	$ 17,374		100.0	$ 18,115		100.0	(4.1)
Cost of products sold	5,282		30.4	5,455		30.1	(3.2)
Selling, marketing and administrative expenses	4,847		27.9	5,183		28.6	(6.5)
Research and development expense	1,899		10.9	1,831		10.1	3.7
In-process research and development	—		—	18		0.1
Interest (income) expense, net	119		0.7	118		0.7
Other (income) expense, net	(348)		(2.0)	86		0.5
Earnings before provision for taxes on income	5,575		32.1	5,424		29.9	2.8
Provision for taxes on income	1,255		7.2	697		3.8	80.1
Net earnings	4,320		24.9	4,727		26.1	(8.6)

Net earnings per share (Diluted)	$ 1.53			$ 1.64			(6.7)

Average shares outstanding (Diluted)	2,826.0			2,874.7

Effective tax rate	22.5	%		12.9	%

Adjusted earnings before provision for taxes and net earnings ^{(1) (A)}
Earnings before provision for taxes on income	$ 5,630		32.4	$ 5,928		32.7	(5.0)
Net earnings	$ 4,418		25.4	$ 4,693		25.9	(5.9)
Net earnings per share (Diluted)	$ 1.56			$ 1.63			(4.3)
Effective tax rate	21.5	%		20.8	%

⁽¹⁾ See Reconciliation of Non-GAAP Financial Measures.

^(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as intangible asset amortization expense, significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as intangible asset amortization expense, the effects of an acquisition, the Ortho-Clinical Diagnostics divestiture, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.



Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)	FIRST QUARTER
			Percent Change
	2015	2014	Total		Operations	Currency
Sales to customers by
segment of business

Consumer
U.S.	$ 1,359	1,309	3.8	%	3.8	—
International	2,031	2,248	(9.7)		3.1	(12.8)
	3,390	3,557	(4.7)		3.4	(8.1)

Pharmaceutical
U.S.	4,371	3,740	16.9		16.9	—
International	3,355	3,758	(10.7)		3.7	(14.4)
	7,726	7,498	3.0		10.2	(7.2)

Medical Devices
U.S.	2,962	3,155	(6.1)		(6.1)	—
International	3,296	3,905	(15.6)		(3.3)	(12.3)
	6,258	7,060	(11.4)		(4.6)	(6.8)

U.S.	8,692	8,204	5.9		5.9	—
International	8,682	9,911	(12.4)		0.8	(13.2)
Worldwide	$ 17,374	18,115	(4.1)	%	3.1	(7.2)



Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)	FIRST QUARTER
			Percent Change
	2015	2014	Total		Operations	Currency
Sales to customers by
geographic area

U.S.	$ 8,692	8,204	5.9	%	5.9	—

Europe	4,040	4,885	(17.3)		0.3	(17.6)
Western Hemisphere excluding U.S.	1,639	1,695	(3.3)		9.9	(13.2)
Asia-Pacific, Africa	3,003	3,331	(9.8)		(3.0)	(6.8)
International	8,682	9,911	(12.4)		0.8	(13.2)

Worldwide	$ 17,374	18,115	(4.1)	%	3.1	(7.2)



Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures

	First Quarter		% Incr. /
(Dollars in Millions Except Per Share Data)	2015	2014	(Decr.)

Earnings before provision for taxes on income - as reported	$ 5,575	5,424	2.8	%
Intangible asset amortization expense	312	368
Litigation gain, net	(402)	—
DePuy ASR^TM Hip program	139	—
Synthes integration costs	32	118
Ortho-Clinical Diagnostics divestiture net gain	(26)	—
In-process research and development	—	18
Earnings before provision for taxes on income - as adjusted	$ 5,630	5,928	(5.0)	%

Net Earnings - as reported	$ 4,320	4,727	(8.6)	%
Intangible asset amortization expense	226	267
Litigation gain, net	(253)	—
DePuy ASR^TM Hip program	122	—
Synthes integration costs	25	84
Ortho-Clinical Diagnostics divestiture net gain	(22)	—
In-process research and development	—	13
Tax benefit associated with Conor Medsystems	—	(398)
Net Earnings - as adjusted	$ 4,418	4,693	(5.9)	%

Diluted Net Earnings per share - as reported	$ 1.53	1.64	(6.7)	%
Intangible asset amortization expense	0.08	0.09
Litigation gain, net	(0.09)	—
DePuy ASR^TM Hip program	0.04	—
Synthes integration costs	0.01	0.03
Ortho-Clinical Diagnostics divestiture net gain	(0.01)	—
In-process research and development	—	0.01
Tax benefit associated with Conor Medsystems	—	(0.14)
Diluted Net Earnings per share - as adjusted	$ 1.56	1.63	(4.3)	%



Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure

Operational Sales Growth Excluding Acquisitions and Divestitures^(A)
FIRST QUARTER 2015 ACTUAL vs. 2014 ACTUAL


Segments

	Consumer	Pharmaceutical	Medical Devices	Total
	Operational % ⁽¹⁾

WW As Reported:	3.4%	10.2%	(4.6)%	3.1%
U.S.	3.8%	16.9%	(6.1)%	5.9%
International	3.1%	3.7%	(3.3)%	0.8%

Women's Health
K-Y ^®	0.7			0.1
U.S.	1.3			0.2
International	0.4			0.1

Wound Care / Other
BENECOL ^®	0.7			0.1
U.S.	0.0			0.0
International	1.2			0.3

Diagnostics
Ortho-Clinical Diagnostics			5.9	2.4
U.S.			7.2	3.0
International			4.8	1.9

All Other Acquisitions and Divestitures	(0.1)			0.0
U.S.	0.0			0.0
International	(0.2)			(0.1)

WW Ops excluding Acquisitions and Divestitures	4.7%	10.2%	1.3%	5.7%
U.S.	5.1%	16.9%	1.1%	9.1%
International	4.5%	3.7%	1.5%	3.0%

⁽¹⁾ Operational growth excludes the effect of translational currency

^(A) NON-GAAP FINANCIAL MEASURE “Operational sales growth excluding the net impact of acquisitions and divestitures” is a non-GAAP financial measure. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. Due to the variable nature of acquisitions and divestitures and the impact they may have on the analysis of underlying business performance and trends, management believes that providing this measure enhances an investor’s understanding of the Company’s performance and may assist in the evaluation of ongoing business operations period over period. This non-GAAP financial measure is presented to permit investors to more fully understand how management assesses the performance of the Company, including for internal evaluation of the performance of the Company's businesses and planning and forecasting for future periods. The use of this non-GAAP financial measure as a performance measure is limited in that it provides a view of the Company's results of operations without including all events during a period and may not provide a comparable view of the Company's performance to that of other companies in the health care industry.



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		FIRST QUARTER
				% Change
		2015	2014	Reported		Operational⁽¹⁾		Currency
CONSUMER SEGMENT⁽²⁾

BABY CARE
US	$	111	102	8.8	%	8.8	%	—	%
Intl		400	443	(9.7	)	(0.9	)	(8.8	)
WW		511	545	(6.2	)	1.0		(7.2	)

ORAL CARE
US		158	160	(1.3	)	(1.3	)	—
Intl		245	251	(2.4	)	8.8		(11.2	)
WW		403	411	(1.9	)	5.0		(6.9	)

OTC
US		405	366	10.7		10.7		—
Intl		588	645	(8.8	)	9.1		(17.9	)
WW		993	1,011	(1.8	)	9.6		(11.4	)

SKIN CARE
US		492	457	7.7		7.7		—
Intl		411	457	(10.1	)	1.5		(11.6	)
WW		903	914	(1.2	)	4.6		(5.8	)

WOMEN'S HEALTH
US		6	24	(75.0	)	(75.0	)	—
Intl		281	303	(7.3	)	5.5		(12.8	)
WW		287	327	(12.2	)	(0.4	)	(11.8	)

WOUND CARE/OTHER
US		187	200	(6.5	)	(6.5	)	—
Intl		106	149	(28.9	)	(19.7	)	(9.2	)
WW		293	349	(16.0	)	(12.1	)	(3.9	)

TOTAL CONSUMER
US		1,359	1,309	3.8		3.8		—
Intl		2,031	2,248	(9.7	)	3.1		(12.8	)
WW	$	3,390	3,557	(4.7	)%	3.4	%	(8.1	)%

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		FIRST QUARTER
				% Change
		2015	2014	Reported		Operational⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (3)}

IMMUNOLOGY
US	$	1,755	1,547	13.4	%	13.4	%	—	%
Intl		708	796	(11.1	)	3.1		(14.2	)
WW		2,463	2,343	5.1		9.9		(4.8	)
REMICADE
US		1,055	997	5.8		5.8		—
US Exports⁽⁴⁾		181	167	8.4		8.4		—
Intl		364	446	(18.4	)	(6.2	)	(12.2	)
WW		1,600	1,610	(0.6	)	2.8		(3.4	)
SIMPONI / SIMPONI ARIA
US		155	104	49.0		49.0		—
Intl		145	155	(6.5	)	9.7		(16.2	)
WW		300	259	15.8		25.5		(9.7	)
STELARA
US		364	279	30.5		30.5		—
Intl		185	177	4.5		22.5		(18.0	)
WW		549	456	20.4		27.4		(7.0	)
OTHER IMMUNOLOGY
US		—	—	—		—		—
Intl		14	18	(22.2	)	(13.7	)	(8.5	)
WW		14	18	(22.2	)	(13.7	)	(8.5	)

INFECTIOUS DISEASES
US		412	561	(26.6	)	(26.6	)	—
Intl		563	639	(11.9	)	4.2		(16.1	)
WW		975	1,200	(18.8	)	(10.2	)	(8.6	)
EDURANT
US		9	5	80.0		80.0		—
Intl		82	76	7.9		30.6		(22.7	)
WW		91	81	12.3		33.6		(21.3	)
OLYSIO / SOVRIAD
US		98	291	(66.3	)	(66.3	)	—
Intl		136	63	*		*		**
WW		234	354	(33.9	)	(26.2	)	(7.7	)
PREZISTA / PREZCOBIX
US		234	214	9.3		9.3		—
Intl		193	231	(16.5	)	(1.6	)	(14.9	)
WW		427	445	(4.0	)	3.7		(7.7	)
OTHER INFECTIOUS DISEASES
US		71	51	39.2		39.2		—
Intl		152	269	(43.5	)	(34.5	)	(9.0	)
WW		223	320	(30.3	)	(22.8	)	(7.5	)

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		FIRST QUARTER
				% Change
		2015	2014	Reported		Operational ⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (3) (Continued)}

NEUROSCIENCE
US	$	750	601	24.8	%	24.8	%	—	%
Intl		868	1,037	(16.3	)	(3.2	)	(13.1	)
WW		1,618	1,638	(1.2	)	7.1		(8.3	)
CONCERTA / METHYLPHENIDATE
US		126	35	*		*		—
Intl		98	115	(14.8	)	(3.5	)	(11.3	)
WW		224	150	49.3		58.0		(8.7	)
INVEGA
US		94	86	9.3		9.3		—
Intl		61	79	(22.8	)	(8.7	)	(14.1	)
WW		155	165	(6.1	)	0.7		(6.8	)
INVEGA SUSTENNA / XEPLION
US		228	182	25.3		25.3		—
Intl		183	191	(4.2	)	12.5		(16.7	)
WW		411	373	10.2		18.7		(8.5	)
RISPERDAL CONSTA
US		104	106	(1.9	)	(1.9	)	—
Intl		150	204	(26.5	)	(13.0	)	(13.5	)
WW		254	310	(18.1	)	(9.2	)	(8.9	)
OTHER NEUROSCIENCE
US		198	192	3.1		3.1		—
Intl		376	448	(16.1	)	(4.5	)	(11.6	)
WW		574	640	(10.3	)	(2.2	)	(8.1	)

ONCOLOGY
US		334	240	39.2		39.2		—
Intl		774	782	(1.0	)	15.7		(16.7	)
WW		1,108	1,022	8.4		21.2		(12.8	)
IMBRUVICA
US		66	6	*		*		—
Intl		50	4	*		*		**
WW		116	10	*		*		**
VELCADE
US		—	—	—		—		—
Intl		339	408	(16.9	)	(4.0	)	(12.9	)
WW		339	408	(16.9	)	(4.0	)	(12.9	)
ZYTIGA
US		253	229	10.5		10.5		—
Intl		303	283	7.1		26.3		(19.2	)
WW		556	512	8.6		19.2		(10.6	)
OTHER ONCOLOGY
US		15	5	*		*		—
Intl		82	87	(5.7	)	10.1		(15.8	)
WW		97	92	5.4		20.3		(14.9	)
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		FIRST QUARTER
				% Change
		2015	2014	Reported		Operational ⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (3) (Continued)}

CARDIOVASCULAR / METABOLISM / OTHER⁽⁵⁾
US	$	1,120	791	41.6	%	41.6	%	—	%
Intl		442	504	(12.3	)	(0.8	)	(11.5	)
WW		1,562	1,295	20.6		25.1		(4.5	)
XARELTO
US		441	319	38.2		38.2		—
Intl		—	—	—		—		—
WW		441	319	38.2		38.2		0.0
INVOKANA / INVOKAMET
US		266	93	*		*		—
Intl		12	1	*		*		**
WW		278	94	*		*		**
PROCRIT / EPREX
US		163	176	(7.4	)	(7.4	)	—
Intl		106	134	(20.9	)	(7.5	)	(13.4	)
WW		269	310	(13.2	)	(7.4	)	(5.8	)
OTHER
US		250	203	23.2		23.2		—
Intl		324	369	(12.2	)	(1.7	)	(10.5	)
WW		574	572	0.3		7.1		(6.8	)

TOTAL PHARMACEUTICAL
US		4,371	3,740	16.9		16.9		—
Intl		3,355	3,758	(10.7	)	3.7		(14.4	)
WW	$	7,726	7,498	3.0	%	10.2	%	(7.2	)%

Supplemental Sales Information
		2014
		Q1	Q2	Q3		Q4		Full Year
INVOKANA / INVOKAMET
US		93	114	169		193		569
Intl		1	3	5		8		17
WW		94	117	174		201		586
IMBRUVICA
US		6	33	42		64		145
Intl		4	9	14		28		55
WW		10	42	56		92		200

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		FIRST QUARTER
				% Change
		2015	2014	Reported		Operational ⁽¹⁾		Currency
MEDICAL DEVICES ⁽²⁾

CARDIOVASCULAR CARE
US	$	228	205	11.2	%	11.2	%	—	%
Intl		301	336	(10.4	)	3.4		(13.8	)
WW		529	541	(2.2	)	6.4		(8.6	)

DIABETES CARE
US		212	192	10.4		10.4		—
Intl		272	320	(15.0	)	0.6		(15.6	)
WW		484	512	(5.5	)	4.2		(9.7	)

DIAGNOSTICS⁽⁶⁾
US		—	224	**		**		—
Intl		30	219	(86.3	)	(83.5	)	(2.8	)
WW		30	443	(93.2	)	(91.8	)	(1.4	)

ORTHOPAEDICS
US		1,309	1,292	1.3		1.3		—
Intl		1,019	1,129	(9.7	)	2.9		(12.6	)
WW		2,328	2,421	(3.8	)	2.1		(5.9	)

SPECIALTY SURGERY / OTHER
US		417	417	0.0		0.0		—
Intl		416	457	(9.0	)	3.5		(12.5	)
WW		833	874	(4.7	)	1.8		(6.5	)

SURGICAL CARE
US		543	539	0.7		0.7		—
Intl		880	969	(9.2	)	3.0		(12.2	)
WW		1,423	1,508	(5.6	)	2.3		(7.9	)

VISION CARE
US		253	286	(11.5	)	(11.5	)	—
Intl		378	475	(20.4	)	(7.5	)	(12.9	)
WW		631	761	(17.1	)	(9.0	)	(8.1	)

TOTAL MEDICAL DEVICES
US		2,962	3,155	(6.1	)	(6.1	)	—
Intl		3,296	3,905	(15.6	)	(3.3	)	(12.3	)
WW	$	6,258	7,060	(11.4	)%	(4.6	)%	(6.8	)%

* Percentage greater than 100%
** Not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Prior year amounts have been reclassified to conform to current year product disclosure
(4) Reported as U.S. sales
(5) Previously referred to as Other
(6) Reflects Diagnostics divestiture June 30, 2014

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2024 to Apr 2024

Click Here for more Johnson and Johnson Charts.

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2023 to Apr 2024

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

JNJ Johnson and Johnson

Latest JNJ Messages

Loading Messages....

Johnson & Johnson News

Loading Messages....

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

JNJ Johnson and Johnson

Latest JNJ Messages

Loading Messages....

Johnson & Johnson News

Loading Messages....

Your Recent History

Company

Business

Popular

Get The App